Drug Profile
FR 194738
Latest Information Update: 09 Oct 2001
Price :
$50
*
At a glance
- Originator Fujisawa
- Class Antihyperlipidaemics
- Mechanism of Action Squalene monooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 09 Oct 2001 No-Development-Reported for Hyperlipidaemia in Japan (PO)
- 23 Jun 1998 Commercial data has been reviewed by Fujisawa
- 06 Jan 1998 New profile